Gambro Acquires Medical Fluids Plant in South Korea

Stockholm, SWEDEN

STOCKHOLM, Sweden, Nov. 4, 2002 (PRIMEZONE) -- Gambro AB (Other OTC:GAMBF) (Stockholm:GAMBa) (Stockholm:GAMBb), a leading international medical technology and healthcare company, today announced that it has acquired a medical fluids production plant owned by the Korean life science company, Green Cross Ltd. The plant is today a major supplier to Gambro in South Korea.

The acquisition will provide local sourcing of concentrates for hemodialysis and a base for production of solutions for peritoneal dialysis for the Korean and Asian markets. Thereby Gambro is strengthening its position in Asia as a leading provider of products and systems for dialysis. The production unit has about 50 employees and will initially serve the Korean market.

For further information please contact:

Bo-Inge Hansson, President
Gambro Renal Products Asia
tel. +86-21-5046 1919

Bengt Modeer, Senior Vice President, Corporate Communications
tel. +46-8-613 65 33, +46-70-513 65 33

Pia Irell, Investor Relations Director, Corporate Finance
tel. +46-8-613 65 91, +46-70-513 65 91

Gambro is a global medical technology and healthcare company with leading positions in renal care -- services and products -- and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with more than 52,700 patients in 688 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with 2001 revenues of approximately SEK 27 billion (USD 2.7 billion), has 20,900 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Jakobsgatan 6, PO Box 7373 SE-103 91
Stockholm, Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30

This information was brought to you by Waymaker

The following files are available for download: